NYSE:BDXMedical Equipment
Becton Dickinson (BDX): Valuation Check After New Cell Analyzers Launch and ChemoGLO Safety Alliance
Recent moves in Becton Dickinson (BDX) have been driven by two MedTech updates: a global rollout of next generation cell analyzers and a new ChemoGLO alliance focused on hazardous drug contamination testing.
See our latest analysis for Becton Dickinson.
Those launches and the ChemoGLO tie up land at a moment when momentum is tentatively improving, with a 90 day share price return of 8.16% but a weaker one year total shareholder return of 9.01%.
If you like the defensive healthcare angle here,...